WATWaters Corporation

$433.70+42% 1Y

$433.70

$283.3252 weeks$443.32

Is the price fair?

Watch

A demanding price: priced for +26% a year vs +16% a year delivered, at the top of its own P/E range, and rich vs its sector.

3 to watch

What the price assumes~+26% a year

Priced for ~26% a year FCF growth. The price demands more than its three-year revenue growth of 16% a year, priced for acceleration.

Vs its own P/E rangedearest in 37 quartersderived

Expensive vs its own history: P/E 108.2 vs a 27.8 median over 37 quarters (+289% vs median).

Vs sector (EV/EBIT)119.7×

Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

Unless marked, from derived, as of Jul 4, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)bottom 5% of the market

FCF yieldbottom 7% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What WAT's price assumes

Waters Corporation trades at 108× earnings against 35.2× for the median Diagnostics & Research name, more expensive than its own group.

108

Trailing P/E · Diagnostics & Research median 35.2 · 3.08× the median: the market pays up for this one

Price / sales: 7.51
Price / sales · today's price, trailing year to Jul 4, 2026
Free cash flow yield: 1.1%
Free cash flow yield · Diagnostics & Research median 3.7%
Growth the price implies: +26%
Growth the price implies · The price pays for +26% free cash flow growth a year for a decade; revenue has grown +16% a year over the last three.